Multiple Sclerosis

🧠 Standard of Care

Multiple Sclerosis (MS) is an autoimmune disease where the body attacks the protective myelin sheath of the nerves. Treatment focuses on speeding recovery from attacks, slowing the progression of the disease, and managing MS symptoms.

• Neurologist Oversight: Care should ideally be directed by a neurologist specializing in MS to properly titrate immunomodulatory drugs.
• Physical and Occupational Therapy: Essential for maintaining mobility, managing spasticity, and adapting to daily challenges.
• Relapse Management: Rapid intervention during acute exacerbations (flare-ups) using high-dose corticosteroids or plasmapheresis to reduce nerve inflammation.

💊 Symptom Management Medications

While disease-modifying therapies treat the underlying cause, symptomatic medications are required to improve quality of life.

Muscle Spasticity (Baclofen, Tizanidine)

Muscle relaxants are commonly prescribed to relieve the painful muscle stiffness or spasms that frequently affect the legs.

Fatigue Management (Amantadine, Modafinil)

Fatigue is one of the most common and debilitating symptoms of MS. These medications can help boost daytime alertness and energy.

Bladder and Bowel Control

Medications like Oxybutynin can help manage an overactive bladder, a common consequence of spinal cord lesions.

💉 Disease-Modifying Therapies (DMTs)

DMTs are designed to lower the relapse rate and slow the formation of new lesions on MRI.

• Injectable Therapies (Interferons, Glatiramer acetate): Traditional, long-standing treatments that modulate the immune system with a well-established safety profile.
• Oral Medications (Dimethyl fumarate, Fingolimod): Convenient daily pills that trap immune cells in the lymph nodes or alter the inflammatory response.
• Infusion Treatments (Ocrelizumab, Natalizumab): Highly effective monoclonal antibodies administered in clinical settings. They target specific B-cells or block immune cells from entering the brain and spinal cord.

🔬 Active Clinical Trials

Researchers are actively testing new interventions to halt progression and repair myelin. Here are some live trials actively recruiting participants:

• NCT06249438 (RenJi Hospital): The CAR-AID study exploring C-CAR168 (CD20/BCMA Chimeric Antigen Receptor Autologous T Cell Product) in treating autoimmune diseases refractory to standard therapy.
• NCT05999604 (Fondation Ophtalmologique Adolphe de Rothschild): The WINDOCRE trial, comparing the impact of annual versus biannual infusions of Ocrelizumab in patients with active MS on radiological disease activity.

❓ Patient FAQ

Q: Is Multiple Sclerosis fatal?
A: In the vast majority of cases, MS is not fatal. Most people with MS have a normal or near-normal life expectancy, though severe complications can occur in very advanced stages.

Q: What causes an MS relapse?
A: A relapse (or flare-up) is caused by inflammation in the central nervous system that damages the myelin sheath. Triggers can include stress, infections (like a cold or flu), and extreme heat.

Q: Does MS always lead to using a wheelchair?
A: No. With early intervention and modern disease-modifying therapies, the majority of people with MS do not become severely disabled and do not require a wheelchair.